Last Updated on December 31, 2023 by The Health Master
The U.S health regulator has declined to approve Gilead Sciences’ injectable drug for the treatment of HIV-1 infection over concerns related to the vials meant for the drug, the company said on Tuesday.
In a so-called complete response letter, the U.S. Food and Drug Administration (USFDA) cited issues related to the compatibility of the drug, lenacapavir, with the proposed borosilicate vial.
“Gilead intends to provide USFDA with a comprehensive plan and corresponding data to use a different vial type,” said Merdad Parsey, chief medical officer of Gilead in a statement.
Gilead, which is also developing the drug for prevention of HIV-1 infection, plans to discuss the concerns with the agency over the coming months to work towards the drug’s approval.
The issue of compatibility of the vials has been an issue since December, when some of the drug’s trials, including those for prevention of HIV-1, were placed on hold by the FDA due to the potential of formation of sub-visible glass particles in the solution of lenacapavir.
The pause was only for injectable lenacapavir. Dosing of oral formulations was allowed to continue.
Gilead’s lenacapavir, meant to be injected under the skin once every six months, was developed for the treatment of patients who have undergone prior therapy and are resistant to multiple existing drugs.
Lenacapavir works by interfering with the activity of HIV capsid, a protein which protects the virus’ genetic material, playing a key role in its replication.
Gilead’s marketing application included data from a mid-to-late-stage trial, which showed lenacapavir, in combination with other antiretrovirals, helped reduce viral load in people living with HIV who were no longer effectively responding to their current therapy.
Gilead already has several U.S. approved HIV treatments, with Biktarvy being its top selling drug in the category, raking in $8.62 billion in 2021.
Why these Pharma Companies are realigning their India operations
USFDA approves this drug for bone marrow cancer treatment
NDPS Exporters and Importers to register with ICEGATE portal: CBN
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
20 projects worth Rs. 840 crore for PLI scheme for Bulk drugs
Drug recall: Aurobindo, Sun Pharma recall these products
CDSCO gives nod to Sun Pharma to conduct Phase 4 clinical…
Drug recall: Medical Device – Infusion Pumps recalled due to this reason
How Antibiotics polluting Indian rivers: Study
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
